LATEST UPDATES » Vol 23, No 01, January 2019 – Taiwan medical tourism - Combining medical travel and tourist destination       » New breast cancer drug now available in China       » Chinese scientists make important cancer finding       » Japan's plan to revolutionise healthcare sector with tech       » GSK to buy oncology drugmaker Tesaro for US$5.1 billion       » There is hope for anticancer vaccines      
EYE ON CHINA For e-subscribers (PDF)
Vol 22, No 01, January 2018
Scientists close in on origin of SARS

Researchers believe deadly virus began in bats in Yunnan province

Chinese Academy of Sciences sets up innovation center in Bangkok

CAS Innovation Cooperation Center (Bangkok) to promote scientific and technological cooperation between China, Thailand and ASEAN.

Chinese researchers map key protein in DNA repair with near-atomic resolution

Provides a molecular blueprint for the development of novel ATR inhibitors as potential cancer therapeutic agents.

AstraZeneca to develop new drugs with Chinese partner

The new company holds exclusive rights to develop and commercialise three potential medicines currently in pre-clinical development from AstraZeneca's pipeline in its main therapy areas of oncology, cardiovascular and metabolic diseases, and respiratory.

European medical training facility opens China office

Aims to assist the development of China's medical education sector

China's biotech industry output to exceed 1.21 trillion dollars by 2020

This will account for over 4 percent of China's GDP by 2020.

Chinese-made ventricular assist device enters clinical testing

VAD is known globally as one of the most effective measures to treat patients with severe heart failure and testing will be conducted in three hospitals.

Novogen to establish China entity to further commercialisation and partnerships in China

Following initial face-to-face discussions with third parties in China, Novogen has signed Letter of Intent with Cedrus Investments, a leading specialist investment bank based in Hong Kong, for advisory services in order to establish a corporate structure and operations in the People's Republic of China.

Eisai's Aricept approved for additional indication of severe Alzheimer's disease in China

Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China.

news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
Asia Pacific Biotech News

APBN Editorial Calendar 2019
Taiwan Medical tourism
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy